Patterns of αvβ3 expression in primary and metastatic human breast cancer as shown by 18F-galacto-RGD PET

Journal of Nuclear Medicine

Volumn 49, Issue 2, 2008, Pages 255-259

  Beer, Ambros J ^a   Niemeyer, Markus ^a   Carlsen, Janette ^a   Sarbia, Mario ^a   N̈ahrig, Jörg ^a   Watzlowik, Petra ^a   Wester, Hans Jürgen ^a   Harbeck, Nadia ^a   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

v 3; Angiogenesis; Breast cancer; Integrins; PET; RGD

Indexed keywords

GALACTOARGINYLGLYCYLASPARTIC ACID F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; CYCLOPEPTIDE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUOROGALACTO RGD; FLUOROGALACTO-RGD; GALACTOSE; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE QUALITY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; COMPARATIVE STUDY; EVALUATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PAGET NIPPLE DISEASE; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL; FEMALE; GALACTOSE; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 38949212117     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.045526     Document Type: Article

References (20)

1. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91-100.
2. Ruoslahti E. Specialization of tumor vasculature. Nat Rev Cancer. 2002;2:83-90.
3. 3 for angiogenesis. Science. 1994;2674:569-571.
4. 3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:9482-9487.
5. 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol. 1996;5:127-135.
6. 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 1995;96:1815-1822.
7. 3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 2002;62:4263-4272.
8. 3: a new prognostic indicator in breast cancer. Clin Cancer Res. 1998;4:2625-2634.
9. Damjanovich L, Fulop B, Adany R, Nemes Z. Integrin expression on normal and neoplastic human breast epithelium. Acta Chir Hung. 1997;36:69-71.
10. Pignatelli M, Cardillo MR, Hanby A, Stamp GW. Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. Hum Pathol. 1992;23:1159-1166.
11. Berry MG, Gui GP, Wells CA, Carpenter R. Integrin expression and survival in human breast cancer. Eur J Surg Oncol. 2004;30:484-489.
12. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol. 2006;24:3282-3292.
13. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781-1785.
14. 18F galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333-1341.
15. 3 expression. J Nucl Med. 2006;47:763-769.
16. 18F]galacto-RGD. PLoS Med. March 29, 2005 [Epub ahead of print].
17. 3 expression in man. Clin Cancer Res. 2006;12:3942-3949.
18. 18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004;15:61-69.
19. Brix G, Bellemann ME, Hauser H, et al. Recovery coefficients for the quantification of the arterial input functions from dynamic PET measurements: experimental and theoretical determination. Nuklearmedizin. 2002;41:184-190.
20. 99mTc- NC100692. J Nucl Med. 2006;47:1434-1439.